218 related articles for article (PubMed ID: 15867496)
1. Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals.
Lohse N; Obel N; Kronborg G; Laursen A; Pedersen C; Larsen CS; Kvinesdal B; Sørensen HT; Gerstoft J
AIDS; 2005 May; 19(8):815-22. PubMed ID: 15867496
[TBL] [Abstract][Full Text] [Related]
2. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.
Mocroft A; Ledergerber B; Viard JP; Staszewski S; Murphy M; Chiesi A; Horban A; Hansen AB; Phillips AN; Lundgren JD;
J Infect Dis; 2004 Dec; 190(11):1947-56. PubMed ID: 15529259
[TBL] [Abstract][Full Text] [Related]
3. No change in viral set point or CD4 cell decline among antiretroviral treatment-naïve, HIV-1-infected individuals enrolled in the Danish HIV Cohort Study in 1995-2010.
Helleberg M; Kronborg G; Larsen CS; Pedersen G; Pedersen C; Obel N; Gerstoft J
HIV Med; 2013 Jul; 14(6):362-9. PubMed ID: 23433434
[TBL] [Abstract][Full Text] [Related]
4. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).
Palella FJ; Armon C; Buchacz K; Chmiel JS; Novak RM; D'Aquila RT; Brooks JT;
J Antimicrob Chemother; 2014 Oct; 69(10):2826-34. PubMed ID: 24942257
[TBL] [Abstract][Full Text] [Related]
6. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
[TBL] [Abstract][Full Text] [Related]
7. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.
Lohse N; Jørgensen LB; Kronborg G; Møller A; Kvinesdal B; Sørensen HT; Obel N; Gerstoft J;
Antivir Ther; 2007; 12(6):909-17. PubMed ID: 17926645
[TBL] [Abstract][Full Text] [Related]
8. Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study.
Thorsteinsson K; Ladelund S; Jensen-Fangel S; Johansen IS; Katzenstein TL; Pedersen G; Storgaard M; Obel N; Lebech AM
BMC Infect Dis; 2012 Nov; 12():293. PubMed ID: 23140254
[TBL] [Abstract][Full Text] [Related]
9. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
10. The road to success. Long-term prognosis for persons living with HIV in Denmark - time trends and risk factors.
Lohse N
Dan Med J; 2016 Feb; 63(2):. PubMed ID: 26836803
[TBL] [Abstract][Full Text] [Related]
11. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.
Ledergerber B; Lundgren JD; Walker AS; Sabin C; Justice A; Reiss P; Mussini C; Wit F; d'Arminio Monforte A; Weber R; Fusco G; Staszewski S; Law M; Hogg R; Lampe F; Gill MJ; Castelli F; Phillips AN;
Lancet; 2004 Jul 3-9; 364(9428):51-62. PubMed ID: 15234856
[TBL] [Abstract][Full Text] [Related]
12. Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy.
Sabin CA; Yee TT; Devereux H; Griffioen A; Loveday C; Phillips AN; Lee CA
AIDS; 2000 May; 14(8):1001-7. PubMed ID: 10853982
[TBL] [Abstract][Full Text] [Related]
13. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
14. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.
Napravnik S; Keys JR; Quinlivan EB; Wohl DA; Mikeal OV; Eron JJ
AIDS; 2007 Apr; 21(7):825-34. PubMed ID: 17415037
[TBL] [Abstract][Full Text] [Related]
15. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study.
Larsen MV; Omland LH; Gerstoft J; Røge BT; Larsen CS; Pedersen G; Obel N; Kronborg G
Scand J Infect Dis; 2010 Dec; 42(11-12):917-23. PubMed ID: 20840000
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
Gutierrez F; Padilla S; Masiá M; Iribarren JA; Moreno S; Viciana P; Muñoz L; Gómez Sirvent JL; Vidal F; López-Aldeguer J; Blanco JR; Leal M; Rodríguez-Arenas MA; Perez Hoyos S;
PLoS One; 2006 Dec; 1(1):e89. PubMed ID: 17183720
[TBL] [Abstract][Full Text] [Related]
17. Triple-class HIV antiretroviral therapy failure in an Australian primary care setting.
Bloch M; Farris M; Tilden D; Gowers A; Cunningham N
Sex Health; 2010 Mar; 7(1):17-24. PubMed ID: 20152091
[TBL] [Abstract][Full Text] [Related]
18. A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression.
Loutfy MR; Genebat M; Moore D; Raboud J; Chan K; Antoniou T; Milan D; Shen A; Klein MB; Cooper C; Machouf N; Rourke SB; Rachlis A; Tsoukas C; Montaner JS; Walmsley SL; Smieja M; Bayoumi A; Mills E; Hogg RS;
J Acquir Immune Defic Syndr; 2010 Dec; 55(4):451-9. PubMed ID: 21105259
[TBL] [Abstract][Full Text] [Related]
19. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease.
Hoffmann C; Chow KU; Wolf E; Faetkenheuer G; Stellbrink HJ; van Lunzen J; Jaeger H; Stoehr A; Plettenberg A; Wasmuth JC; Rockstroh J; Mosthaf F; Horst HA; Brodt HR
Br J Haematol; 2004 May; 125(4):455-62. PubMed ID: 15142115
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]